Diabetes Obesity and Cardiometabolic CARE
Weighing the Risks and Benefits of Microdosing Tirzepatide Vials
By Anne M. Komé, Shelby Tungate Lopez, Alissa V. Russell and 1 others.
Abstract
Tirzepatide for chronic weight management is available in single-use autoinjector pens, multi-dose pens, and single-dose vials (1).Tirzepatide multi-dose vials are approved but not yet commercially available (1).We previously described the rationale for microdosing semaglutide and tirzepatide in multi-dose pens (2,3).The same rationale can be applied to tirzepatide vials.
Keywords
- Cardiac pacing and defibrillation studies
- Vial
- Risk assessment
- Data collection
- MicroDose
- Open access
Source
Published in Diabetes Obesity and Cardiometabolic CARE. The abstract is shown as published and remains the work of its authors; read the full article at the source.
Prognia lists this article for reference and education. It is not medical advice. Always read the original and follow current guidelines and local protocols before acting on it.
